Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
ESPN3d
Former D-backs reliever Sewald joins Guardians on one-year deal
He's the third reliever to leave the AL Central champions this winter, following Eli Morgan and Nick Sandlin, who were both traded.
GlobalData on MSN10d
JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400m
Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.
The Washington Post3d
Reliever Paul Sewald and Guardians agree to $7 million, 1-year contract
He’s the third reliever to leave the AL Central champions this winter, following Eli Morgan and Nick Sandlin, who were both traded.
STAT12d
Eli Lilly scientific chief Skovronsky says Scorpion deal ‘checked all the boxes’
Eli Lilly’s chief scientific officer said the company purchased a cancer drug from the startup Scorpion Therapeutics because ...
Yahoo Finance2d
Eli Lilly and Company (LLY)
such as Eli Lilly's Zepbound or Novo Nordisk's Wegovy -- they've made headlines as demand for them soared. The obesity drug market may reach beyond $100 billion by 2030, according to Morgan ...